These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16039891)

  • 41. Emerging treatment for congenital adrenal hyperplasia.
    White PC
    Curr Opin Endocrinol Diabetes Obes; 2022 Jun; 29(3):271-276. PubMed ID: 35283460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Glucocorticoids in pediatrics].
    Radmanović SZ
    Srp Arh Celok Lek; 1995 Jun; 123 Suppl 1():58-62. PubMed ID: 18193804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Growth pattern and final height in 21-hydroxylase deficiency.
    Bajpai A; Pandey RM; Kabra M; Menon PS
    Indian Pediatr; 2007 Oct; 44(10):771-3. PubMed ID: 17998577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging medical therapies for congenital adrenal hyperplasia.
    Speiser PW
    F1000Res; 2019; 8():363. PubMed ID: 30984389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis.
    Muthusamy K; Elamin MB; Smushkin G; Murad MH; Lampropulos JF; Elamin KB; Abu Elnour NO; Gallegos-Orozco JF; Fatourechi MM; Agrwal N; Lane MA; Albuquerque FN; Erwin PJ; Montori VM
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4161-72. PubMed ID: 20823467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia?
    Mooij CF; Kroese JM; Claahsen-van der Grinten HL; Tack CJ; Hermus AR
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):137-46. PubMed ID: 19719762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Surgical management of congenital adrenal hyperplasia in young girls].
    Mure PY; Gelas T; Ripepi M; Hoch M; Mouriquand P
    Prog Urol; 2003 Dec; 13(6):1381-91. PubMed ID: 15000319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Catch-up growth in autosomal dominant isolated growth hormone deficiency (IGHD type II).
    Binder G; Iliev DI; Mullis PE; Ranke MB
    Growth Horm IGF Res; 2007 Jun; 17(3):242-8. PubMed ID: 17360215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel treatment strategies in congenital adrenal hyperplasia.
    Turcu AF; Auchus RJ
    Curr Opin Endocrinol Diabetes Obes; 2016 Jun; 23(3):225-32. PubMed ID: 27032061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Absence of exercise-induced leptin suppression associated with insufficient epinephrine reserve in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Riepe FG; Krone N; Krüger SN; Sweep FC; Lenders JW; Dötsch J; Mönig H; Sippell WG; Partsch CJ
    Exp Clin Endocrinol Diabetes; 2006 Mar; 114(3):105-10. PubMed ID: 16636975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lost lessons of glucocorticoid potency and the treatment of children with congenital adrenal hyperplasia.
    Rivkees SA
    J Pediatr Endocrinol Metab; 2008 Apr; 21(4):297-9. PubMed ID: 18556959
    [No Abstract]   [Full Text] [Related]  

  • 52. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Congenital adrenal hyperplasia: problems with developmental anomalies of the external genitalia and sex assignment.
    Al-Maghribi H
    Saudi J Kidney Dis Transpl; 2007 Sep; 18(3):405-13. PubMed ID: 17679754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Steroid responsive hypertension secondary to 11-beta hydroxylase deficiency--a case report.
    Isiavwe AR; Ekpebegh CO; Fasanmade OA; Ohwovoriole AE
    West Afr J Med; 2008 Jul; 27(3):182-5. PubMed ID: 19256327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Congenital adrenal hyperplasia.
    New MI; Newfield RS
    Curr Ther Endocrinol Metab; 1997; 6():179-87. PubMed ID: 9174733
    [No Abstract]   [Full Text] [Related]  

  • 56. [Tyrosine content in the blood as an index of the adequacy of glucocorticoid replacement therapy in congenital adrenal cortical dysfunction in children].
    Rass IT; Kuznetsova ES; Zhukovskiĭ MA
    Pediatriia; 1979 Sep; (9):26-9. PubMed ID: 492854
    [No Abstract]   [Full Text] [Related]  

  • 57. Growth and development: congenital adrenal hyperplasia-glucocorticoids and height.
    Speiser PW
    Nat Rev Endocrinol; 2010 Jan; 6(1):14-5. PubMed ID: 20010965
    [No Abstract]   [Full Text] [Related]  

  • 58. Bone: low-dose glucocorticoid replacement does not reduce BMD.
    Glover J
    Nat Rev Endocrinol; 2011 Nov; 8(1):3. PubMed ID: 22045109
    [No Abstract]   [Full Text] [Related]  

  • 59. Glucocorticoids in the treament of endocrine disorders.
    Orr FR
    Appl Ther; 1967 Mar; 9(3):257-8. PubMed ID: 6039126
    [No Abstract]   [Full Text] [Related]  

  • 60. Medical treatment of classic and nonclassic congenital adrenal hyperplasia.
    Speiser PW
    Adv Exp Med Biol; 2011; 707():41-5. PubMed ID: 21691951
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.